BiotechTube

MK-0524A + MK-0524A

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypercholesterolemia, Familial

Conditions

Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia

Trial Timeline

Jun 1, 2012 → Dec 1, 2012

NCT ID
NCT01583647

About MK-0524A + MK-0524A

MK-0524A + MK-0524A is a phase 1 stage product being developed by Merck for Hypercholesterolemia, Familial. The current trial status is terminated. This product is registered under clinical trial identifier NCT01583647. Target conditions include Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01583647Phase 1Terminated

Competing Products

20 competing products in Hypercholesterolemia, Familial

See all competitors
ProductCompanyStageHype Score
Evacetrapib + Ezetimibe + Atorvastatin + PlaceboEli LillyPhase 3
77
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
85
Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved
85
colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
85
colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
colesevelam HCl + placeboDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed-dose combination with ezetimibeDaiichi SankyoPre-clinical
23
colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Bempedoic Acid 180Mg/Ezetimibe 10Mg TabDaiichi SankyoPre-clinical
23
Colesevelam Hydrochloride + Ezetimibe + SimvastatinDaiichi SankyoApproved
85
pravastatin tablets and Welchol tablets + pravastatin tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
atrovastatinAstellas PharmaPre-clinical
23
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mgEli LillyApproved
85
PPAR alpha + atorvastatin + placeboEli LillyPhase 2
52
Evacetrapib + PlaceboEli LillyPhase 3
77
LY3015014 + Placebo + Statin + EzetimibeEli LillyPhase 2
52
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85